GlycoMimetics Inc GLYC
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if GLYC is a good fit for your portfolio.
News
-
GlycoMimetics Reports Highlights and Financial Results for Fourth Quarter and Full Year 2023
-
GlycoMimetics to Report Fourth Quarter and 2023 Full Year Financial Results on March 27, 2024
-
GlycoMimetics to Participate in Upcoming Cowen 44th Annual Health Care Conference
-
GlycoMimetics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
-
GlycoMimetics Announces Positive Initial Safety and Pharmacokinetic Results from Phase 1a Healthy Volunteer Study of GMI-1687
Trading Information
- Previous Close Price
- $3.18
- Day Range
- $2.91–3.06
- 52-Week Range
- $1.12–3.35
- Bid/Ask
- $3.01 / $3.07
- Market Cap
- $194.47 Mil
- Volume/Avg
- 282,417 / 327,807
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
GlycoMimetics Inc is a clinical stage biotechnology company. It is focused on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in which carbohydrate biology plays a key role. Glycomimetics are molecules that mimic the structure of carbohydrates involved in important biological processes. Using expertise in carbohydrate chemistry and knowledge of carbohydrate biology, the company is developing a pipeline of proprietary glycomimetics that may inhibit disease-related functions of carbohydrates, such as the roles it plays in inflammation, cancer, and infection.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 39
- Website
- https://www.glycomimetics.com
Comparables
Valuation
Metric
|
GLYC
|
SWTX
|
ATXS
|
---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 4.40 | 5.88 | 3.78 |
Price/Sales | — | 580.59 | — |
Price/Cash Flow | — | — | — |
Price/Earnings
GLYC
SWTX
ATXS
Financial Strength
Metric
|
GLYC
|
SWTX
|
ATXS
|
---|---|---|---|
Quick Ratio | 7.76 | 6.21 | 21.34 |
Current Ratio | 8.14 | 6.41 | 21.73 |
Interest Coverage | — | — | — |
Quick Ratio
GLYC
SWTX
ATXS
Profitability
Metric
|
GLYC
|
SWTX
|
ATXS
|
---|---|---|---|
Return on Assets (Normalized) | −59.22% | −39.61% | −23.26% |
Return on Equity (Normalized) | −67.86% | −45.43% | −44.07% |
Return on Invested Capital (Normalized) | −70.86% | −49.28% | −28.94% |
Return on Assets
GLYC
SWTX
ATXS
Biotechnology Industry Comparables
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Ryqhpmtj | Pzjm | $571.0 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Sdzrjyf | Gkpxps | $107.8 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Pxvmrmpw | Dmxblqh | $106.1 Bil | |
MRNA
| Moderna Inc | Tcyxhfpt | Hcwg | $42.3 Bil | |
ARGX
| argenx SE ADR | Pvcdclfpv | Dzhzw | $23.7 Bil | |
BNTX
| BioNTech SE ADR | Vmdlytd | Vlkjz | $22.1 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Djjjwbrr | Ltxsgcx | $19.4 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Dwffxvy | Jgbjsbn | $16.7 Bil | |
RPRX
| Royalty Pharma PLC Class A | Ylnccnycv | Whxbtp | $13.6 Bil | |
INCY
| Incyte Corp | Rzbysvf | Nmpdr | $12.8 Bil |